{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:25Z","timestamp":1788961705644,"version":"build-2803163510"},"reference-count":56,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["497263"],"award-info":[{"award-number":["497263"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pharmacokinetic studies suggest that specific prostate cancer therapies may alter the metabolism of direct oral anticoagulants (DOACs), leading to elevated risks of thrombosis or bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To assess the risk of thrombosis or bleeding, population\u2010based, retrospective, parallel analyses were conducted in Ontario and Alberta, Canada, among adults patients with prostate cancer who were prescribed a DOAC and a potentially interacting androgen receptor pathway inhibitor (including enzalutamide, apalutamide, or abiraterone) compared with non\u2010DOACs between 2012 and 2023. Analyses were stratified based on a DOAC\u2010inducer cohort (enzalutamide or apalutamide, which might increase the risk of thrombosis) and a DOAC\u2010inhibitor cohort (abiraterone, which might increase the risk of bleeding). Overlap weighted Cox proportional hazard models accounting for 37 covariates were performed independently in each jurisdiction and were pooled using random\u2010effects meta\u2010analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2997 individuals were included (2107 from Ontario and 890 from Alberta). In patients who received enzalutamide or apalutamide, there was no increased risk of all thrombosis in the DOAC groups compared with the non\u2010DOAC groups (pooled hazard ratio, 0.83; 95% confidence interval, 0.36\u20131.93). In patients who received abiraterone, no significant differences were observed in any bleeding events comparing the DOAC and non\u2010DOAC groups (pooled hazard ratio, 1.16; 95% confidence interval, 0.10\u201313.99). The results were consistent in multiple sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs did not contribute to clinically meaningful changes in the risk of thrombosis or bleeding in individuals with prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70266","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:01:06Z","timestamp":1773039666000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-9000","authenticated-orcid":false,"given":"Tzu\u2010Fei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medicine University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Clarke","sequence":"additional","affiliation":[{"name":"ICES Ottawa Hospital Research Institute, The Ottawa Hospital  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Rath","sequence":"additional","affiliation":[{"name":"Alberta Health Services Provincial Research and Data Services University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Yoo","sequence":"additional","affiliation":[{"name":"ICES Ottawa Hospital Research Institute, The Ottawa Hospital  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena","family":"Fremont","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ravani","sequence":"additional","affiliation":[{"name":"Division of Nephrology Cumming School of Medicine University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Boss\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Talarico","sequence":"additional","affiliation":[{"name":"ICES Ottawa Hospital Research Institute, The Ottawa Hospital  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Prostate cancer statistics","author":"Canadian Cancer Society","year":"2023"},{"key":"e_1_2_10_3_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, version 2.2020","author":"National Comprehensive Cancer Network (NCCN)","year":"2020"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5401"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2007.02374.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102021\u2010055485"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(10)70038\u20103"},{"key":"e_1_2_10_8_1","volume-title":"Drug Use Among Seniors on Public Drug Programs in Canada, 2012","author":"Canadian Institute for Health Information (CIHI)","year":"2014"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcy040"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.06.026"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.008987"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010694"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1711948"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.8034"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14662"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915103"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.09.037"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1814468"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1814630"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01461"},{"key":"e_1_2_10_21_1","volume-title":"NCCN Guidelines in Cancer\u2010Associated Venous Thromboembolic Disease. Version 2.2025","author":"National Comprehensive Cancer Network (NCCN)","year":"2025"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003442"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14478"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1225037"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200342010\u201000003"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010199835050\u201000003"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.09.008"},{"issue":"1","key":"e_1_2_10_28_1","article-title":"Abstract 12118: Patterns of anticoagulation use in atrial fibrillation and active cancer: observations from Medicare","volume":"114","author":"Chen S","year":"2021","journal-title":"Circulation"},{"key":"e_1_2_10_29_1","volume-title":"Product Monograph, Including Patient Medication Information: PrXtandi\u00ae enzalutamide capsules","author":"Astellas Pharma Canada, Inc","year":"2024"},{"key":"e_1_2_10_30_1","volume-title":"Product Monograph, Including Patient Medication Information: PrERLEADA\u2122 apalutamide tables","author":"Janssen Inc","year":"2018"},{"key":"e_1_2_10_31_1","volume-title":"Product Monograph: PrZYTIGA\u00ae abiraterone acetate tables","author":"Janssen Inc","year":"2018"},{"issue":"2","key":"e_1_2_10_32_1","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy AR","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12911\u2010015\u20100155\u20105"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1358863x15573839"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449288"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000004554"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.06.015"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010017\u20100361\u20101"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.10.035"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.2016.1260466"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7819"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.12"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7140"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"e_1_2_10_47_1","volume-title":"Cancer statistics at a glance","author":"Canadian Cancer Society","year":"2025"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013\u20100239"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab065"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103599"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193336"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.09.039"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20200055"},{"issue":"1","key":"e_1_2_10_54_1","first-page":"445","article-title":"Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: a post\u2010hoc analysis of TITAN and SPARTAN studies","volume":"12","author":"Potdar R","year":"2022","journal-title":"Am J Cancer Res"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735\u20101097(96)00018\u20106"},{"key":"e_1_2_10_56_1","doi-asserted-by":"crossref","unstructured":"ManuelDG RosellaLC StukelTA.Importance of accurately identifying disease in studies using electronic health records. BMJ. 2010;341:c4226. doi:10.1136\/bmj.c4226 2010.","DOI":"10.1136\/bmj.c4226"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010022\u201001289\u20101"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:39:25Z","timestamp":1775536765000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,15]]}},"alternative-id":["10.1002\/cncr.70266"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70266","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70266"}}